#LFWD

StockTitan

@stocktitan.net

2 days ago

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company Lifeward (Nasdaq: LFWD) received shareholder approval to close a strategic partnership with Oramed (Nasdaq: ORMP) that integrates Oramed’s POD™ oral protein delivery platform into Lifeward while Oramed acquires a significant equity stake.The structure provides Lifeward potential access to up to $47 million, keeps Oramed responsible for POD™ clinical funding, and aims to combine near‑term MedTech profitability with long‑term biotech upside.

#LFWD Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

www.stocktitan.net/news/LFWD/lifeward-recei...

StockTitan

@stocktitan.net

1 week ago

Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton Lifeward (Nasdaq: LFWD) announced a collaboration with Shirley Ryan AbilityLab to launch dedicated clinic days in Q2 2026 to accelerate evaluation and access to the ReWalk Personal Exoskeleton for people with spinal cord injury (SCI).Shirley Ryan AbilityLab will lead clinical evaluation, training and patient support, while Lifeward provides ReWalk, an FDA-cleared wearable robotic system enabling standing, walking, and navigation of stairs and curbs.

#LFWD Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton

www.stocktitan.net/news/LFWD/lifeward-annou...

StockTitan

@stocktitan.net

2 months ago

Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Lifeward (Nasdaq: LFWD) entered a strategic partnership with Oramed (Nasdaq: ORMP) under which Lifeward will acquire Oramed's clinical-stage POD™ protein oral delivery platform and Oramed may acquire up to 49.99% of Lifeward. The transaction provides Lifeward access to up to $47 million via equity, convertible notes, milestone funding and warrants, and includes Oramed funding and managing planned POD™ clinical work.The deal includes a 4% net-sales royalty on ReWalk for up to 10 years and preserves Lifeward’s focus on achieving cash‑flow profitability while adding biotech upside tied to oral insulin and other protein therapies.

#LFWD Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

www.stocktitan.net/news/LFWD/lifeward-enter...

StockTitan

@stocktitan.net

2 months ago

Oramed and Lifeward Announce Strategic Transaction Oramed Pharmaceuticals and Lifeward (NASDAQ: LFWD) signed binding agreements dated January 13, 2026 to transfer Oramed's POD™ oral drug delivery platform to Lifeward in exchange for Oramed receiving a 49.9% beneficial ownership interest upon satisfaction of closing conditions. Lifeward will issue two $10 million senior secured convertible notes (8% interest) with 100% warrant coverage; Oramed to invest $9M in each note. Oramed will fund and manage the upcoming clinical trial and receive 4% of net ReWalk sales for up to 10 years. Lifeward reported $26M revenue from ReWalk and AlterG in the last four quarters.

#LFWD #ORMP Oramed and Lifeward Announce Strategic Transaction

www.stocktitan.net/news/LFWD/oramed-and-lif...

StockTitan

@stocktitan.net

2 months ago

Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates Lifeward (Nasdaq: LFWD) announced a distribution agreement with Singapore-based Verita Neuro to exclusively distribute the ReWalk Personal Exoskeleton initially in Mexico, Thailand, and the United Arab Emirates effective Dec. 17, 2025.Verita will integrate ReWalk into intensive, daily in-patient neurorehabilitation programs and offer patient-specific setup and training, leveraging an international database of >25,000 spinal cord injury patients. Lifeward said the partnership supports a partner-led, capital-efficient commercial expansion and cites a $1.75 billion total addressable market for ReWalk.

#LFWD Lifeward Expands International Distribution of its ReWalk® Personal Robotic Exoskeleton into Mexico, Thailand, and the United Arab Emirates

www.stocktitan.net/news/LFWD/lifeward-expan...

StockTitan

@stocktitan.net

4 months ago

Lifeward Ltd. Reports Third Quarter 2025 Financial Results Lifeward (Nasdaq: LFWD) reported Q3 2025 results on Nov 14, 2025: revenue $6.2M (Q3 2024: $6.1M), net loss $3.2M or $0.20 per share, and cash used in operations $3.8M.Key operational progress included a record quarter of ReWalk placements for Medicare beneficiaries, a 16% year‑over‑year reduction in quarterly cash burn, a 27% decline in quarterly non‑GAAP operating loss, and CE mark approval for ReWalk 7 enabling sales in Europe (~40% of exoskeleton sales). Lifeward also secured a $3.0M loan from Oramed and reaffirmed 2025 guidance of $24–$26M revenue and $12–$14M non‑GAAP net loss.

#LFWD Lifeward Ltd. Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/LFWD/lifeward-ltd-r...

StockTitan

@stocktitan.net

6 months ago

First-Ever Medicare Advantage Payment: Lifeward's ReWalk 7 Exoskeleton Coverage Milestone Opens New Market Medical tech leader Lifeward achieves landmark Medicare Advantage payment for ReWalk 7 exoskeleton. Claims now processed in 30-60 days, with majority approved on first submission.

#LFWD First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton

www.stocktitan.net/news/LFWD/first-commerci...

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Lifeward Sales Fall 15%, Miss Forecast | The Motley Fool

#LFWD #bde0e3e9-2199-423c-b298-915c2de15a2f #data-news

Origin | Interest | Match

StockTitan

@stocktitan.net

7 months ago

Lifeward Ltd. Reports Second Quarter 2025 Financial Results Lifeward Ltd. (NASDAQ: LFWD) reported Q2 2025 financial results, showing mixed performance with revenue of $5.7 million, down 15% year-over-year but up 14% sequentially. The company achieved significant operational milestones, including FDA clearance for ReWalk 7 and record Medicare beneficiary placements.Key financial metrics include a 43.9% gross margin and reduced quarterly cash burn to $3.9 million. The company reported a net loss of $6.6 million, or $0.58 per share. Lifeward appointed new leadership with Mark Grant as CEO and Almog Adar as CFO, while updating 2025 guidance to $24-26 million in revenue.Notable achievements include successful transition to in-house manufacturing, expanded U.S. payer base, and positive Medicare rulings establishing ReWalk as "reasonable and necessary" for beneficiaries.

#LFWD Lifeward Ltd. Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/LFWD/lifeward-ltd-r...

StockTitan

@stocktitan.net

7 months ago

Lifeward Taps Major UK Partner to Launch Medical Tech Expansion Across 6 Gulf Nations Strategic partnership brings AlterG medical devices to UAE and Gulf region through proven distributor with 300+ unit sales track record. See expansion details.

#LFWD Lifeward Expands Distribution Partnership with SportsMed Ltd. to Add Coverage for United Arab Emirates and Entire Gulf Cooperation Council Region

www.stocktitan.net/news/LFWD/lifeward-expan...

StockTitan

@stocktitan.net

8 months ago

Lifeward Announces Pricing of $2.6 Million Public Offering Lifeward (NASDAQ: LFWD), a medical technology company, has announced the pricing of a $2.6 million public offering. The offering consists of 4,000,000 ordinary shares with accompanying warrants at a combined price of $0.65 per share and warrant.The warrants will have an exercise price of $0.65, be immediately exercisable, and expire in five years. If fully exercised, they could generate an additional $2.6 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The company plans to use the proceeds for commercial efforts, working capital, and general corporate purposes, with closing expected around June 26, 2025.

#LFWD Lifeward Announces Pricing of $2.6 Million Public Offering

www.stocktitan.net/news/LFWD/lifeward-annou...

StockTitan

@stocktitan.net

8 months ago

Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary  Lifeward Ltd.,

#LFWD Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary

www.stocktitan.net/news/LFWD/administrative...

StockTitan

@stocktitan.net

10 months ago

Lifeward Q1 Earnings Show Medicare Breakthrough: First Major US Insurer Approves Revolutionary ReWalk 7 Exoskeleton First commercial insurance approval for ReWalk 7, 42.2% margins despite revenue dip to $5M. New partnerships expand market reach. See full financial impacts.

#LFWD Lifeward Ltd. Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/LFWD/lifeward-ltd-r...

StockTitan

@stocktitan.net

10 months ago

Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons Lifeward (NASDAQ: LFWD) has completed a three-year research program with the Israel Innovation Authority's Human Robot Interaction Consortium to integrate AI technology into ReWalk Exoskeletons. The company successfully demonstrated a proof-of-concept prototype that combines advanced sensing technologies and AI for autonomous decision-making in different environments. The research, conducted in collaboration with universities and companies, focused on developing social capabilities for robots and improving human-exoskeleton interactions. The program, which ran from May 2022 to April 2025, aimed to make exoskeletons more intuitive, easier to use, and widely accepted through the integration of AI, sensing technologies, and machine vision. Lifeward was one of six companies participating in the consortium.

#LFWD Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

www.stocktitan.net/news/LFWD/lifeward-compl...

StockTitan

@stocktitan.net

10 months ago

First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton,

#LFWD First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton

www.stocktitan.net/news/LFWD/first-major-u-...

StockTitan

@stocktitan.net

10 months ago

Revolutionary ReWalk Exoskeleton Helps Paralyzed Israeli Soldier Walk: Military Healthcare Breakthrough First-ever military application of ReWalk technology enables paralyzed IDF soldier to walk. Israeli Defense Ministry evaluates broader veteran program. See breakthrough details.

#LFWD Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton

www.stocktitan.net/news/LFWD/paralyzed-isra...

StockTitan

@stocktitan.net

11 months ago

Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market Lifeward (NASDAQ: LFWD) has launched the ReWalk 7 Personal Exoskeleton in the U.S. market, following FDA clearance in March 2025. This seventh-generation exoskeleton for individuals with spinal cord injury (SCI) features significant improvements including:Customizable walking speeds for indoor/outdoor environmentsCrutch Control system for enhanced user controlWrist Control smartwatch and MyReWalk mobile app integrationImproved battery life and seamless stairs/curbs navigationNew therapist handheld device for trainingThe development involved extensive testing with dozens of end users and physical therapists. This launch follows two major milestones: the 2023 addition of stairs and curbs navigation capability to ReWalk 6.0, and the 2024 establishment of a Medicare reimbursement pathway by CMS for personal exoskeletons.

#LFWD Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market

www.stocktitan.net/news/LFWD/lifeward-launc...

StockTitan

@stocktitan.net

1 year ago

Revolutionary ReWalk 7 Exoskeleton Gets FDA Green Light, Medicare Coverage Ready Latest FDA-cleared exoskeleton enables walking for SCI patients, backed by Medicare coverage. ReWalk 7 brings enhanced features to revolutionary medical device technology.

#LFWD FDA Issues Clearance for ReWalk 7 Exoskeleton

www.stocktitan.net/news/LFWD/fda-issues-cle...

StockTitan

@stocktitan.net

1 year ago

Can Lifeward's 85% Revenue Growth Transform the Medical Device Market? Q4 Results Reveal Key Shifts Record-breaking year with Medicare coverage driving ReWalk sales. Strategic growth plan targets profitability by Q4 2025 with expanded product lines and streamlined operations.

#LFWD Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/LFWD/lifeward-ltd-r...

StockTitan

@stocktitan.net

1 year ago

Revolutionary Exoskeleton Technology Gains Major Workers' Comp Distribution Channel - What This Means for SCI Treatment Strategic partnership with CorLife grants exclusive distribution rights for ReWalk's innovative exoskeleton, expanding access through workers' compensation channels.

#LFWD Lifeward and CorLife Finalize Partnership to Expand Workers’ Compensation Access to ReWalk Exoskeleton

www.stocktitan.net/news/LFWD/lifeward-and-c...

StockTitan

@stocktitan.net

1 year ago

Lifeward's 13-Year CEO Exit Raises Questions About Company's Next Chapter CEO Larry Jasinski to retire after 13 years amid $25.7M revenue report. Board launches successor search as company postpones investor event to 2025.

#LFWD Lifeward Announces CEO Transition

www.stocktitan.net/news/LFWD/lifeward-annou...

InsiderFinance

@insiderfinance.com

1 year ago

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #LFWD 149.8x
2. #SW 76.0x
3. #VLY 40.0x
4. #PZZA 37.6x
5. #REAL 22.7x

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

1 year ago

German Healthcare Giant BARMER to Cover Revolutionary ReWalk Exoskeletons for 8.5M Patients Major breakthrough as Lifeward partners with BARMER to provide ReWalk Exoskeletons to 8.5M German beneficiaries, expanding coverage to 45% of Germany's insured population.

#LFWD Lifeward Finalizes Personal Exoskeleton Reimbursement Agreement with BARMER, Adding 8.5 Million Covered Lives in Germany

www.stocktitan.net/news/LFWD/lifeward-final...

StockTitan

@stocktitan.net

1 year ago

Lifeward Doubles ReWalk System Sales, Secures Medicare Coverage in Breakthrough 2024 Lifeward achieved key milestones with Medicare exoskeleton classification, 70+ ReWalk systems deployed, and AlterG's 90% growth. Company targets profitability by H2 2026.

#LFWD Lifeward CEO Issues Year-End 2024 Open Letter to Shareholders and Provides 2025 Commercial and Operational Priorities

www.stocktitan.net/news/LFWD/lifeward-ceo-i...

StockTitan

@stocktitan.net

1 year ago

Lifeward Secures $5 Million Through Strategic Share Offering at $2.75 Per Share Lifeward announces registered direct offering of 1.8M shares with concurrent warrant placement. Funds targeted for commercial expansion and working capital needs.

#LFWD Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/LFWD/lifeward-annou...

InsiderFinance

@insiderfinance.com

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#JOBY, #GCI, #CCL, #RIVN, #LFWD

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

1 year ago

#LFWD Coverage for ReWalk Personal Exoskeleton Expands as Hungary Joins the U.S. and Germany with a Policy Providing Access to Exoskeletons

www.stocktitan.net/news/LFWD/coverage-for-r...